Abbvie Inc.

Omar J Shah

Helmut Mack

Bryan K Sorensen

Anil Vasudevan

Todd M Hansen

Michael Michaelides

Kevin R Woller

Marina Pliushchev

Ramzi Farah Sweis

Howard Robin Heyman

Chris Tse

Richard F Clark

Michael L Curtin

Mark Anderson

Xiaoyu Lin

Michael L Curtain

Xiaoli Huang

Junling Li

Leiming Li

Rick F Clark

Yu Shen

Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

NAMPT and ROCK inhibitors

Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.

NAMPT and rock inhibitors

The present disclosure relates to a combination of therapeutic agents for use in treating a patient a subject suffering from cancer. In addition, the present disclosure also relates to diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.

Combination therapy for treating cancer and diagnostic assays for use therein

Growing community of inventors

Issaquah, WA, United States of America

Omar J Shah